Email Updates

You are here

Home

16 OCTOBER 2020 VOLUME 22 ISSUE 40

Media Coverage

  • ‘Corona Carriers’: Stigma Halts Medication and Meet-Ups for HIV+ Malawians

    Malawian student Kondwani has fought against the stigma of being HIV-positive for most of his life, but COVID-19 has reignited old prejudices and given rise to a new term of abuse - “corona carrier”.

    October 15, 2020
    Treatment
    Reuters

  • Biological, Clinical and Ethical Imperatives for Involving Diverse Women in HIV Clinical Trials

    Clinical trials have historically under-enrolled women, and research has too often ignored that females and males are biologically different, although women are disproportionately affected by HIV in sub-Saharan Africa. Women’s exclusion from trials is often motivated by a desire to protect them and their children from potential harm caused by a medication, but this results in inequity for women: unknown safety, efficacy and tolerance of most new medications.

    October 15, 2020
    General
    aidsmap

  • WHO Estimates 20 Percent More TB Cases in SA Than Previously Thought

    Around 20 percent more people are falling ill with tuberculosis (TB) in South Africa than previously thought. This emerged from new estimates contained in the 2020 WHO World TB Report launched today and published on the World Health Organization (WHO) website.

    October 14, 2020
    General
    Spotlight

  • What Happened With PEPFAR’s Faith-Based Initiative?

    On World AIDS Day in 2018, Vice President Mike Pence announced a new US President’s Emergency Plan for AIDS Relief initiative that would provide an additional $100 million to faith-based organizations. It was a flashy announcement that raised concerns over where the funding would come from and whether it would be politics or evidence that determined the initiative’s direction.

    October 14, 2020
    General
    Devex

  • High Hopes for Study on Injections Preventing HIV in Women

    Arguably the most eagerly awaited study findings in HIV are from research on an antiretroviral (ARV) injection that may prevent HIV infection in women. If it works, the option of getting an injection every two months could provide women with a new way to prevent HIV infection – something that could be empowering for women who are not in a position to negotiate condom use or who cannot take pills to prevent HIV infection.

    October 14, 2020
    PrEP
    Daily Maverick

  • The World Could See a COVID-19 Vaccine by Next Year — Here’s Who Will Get It and How

    Even if a jab is shown to work, there won’t be enough doses for everyone. Countries such as South Africa would need to make tough decisions about who it would give the vaccine to — and more importantly how to create a system to get it to them.

    October 14, 2020
    General
    Bhekisisa

  • Heterosexual Men Likely to Have Unmet HIV Treatment Needs

    Women with HIV and men with HIV who have sex with women (MSW) have substantially different experiences with treatment than men with HIV who have sex with men (MSM), according to findings presented at the HIV Glasgow 2020 Virtual Meeting. MSM had better overall health outcomes than the other two groups, the study found, suggesting that MSW and women have unmet needs that require providers' attention.

    October 13, 2020
    General
    Medscape

  • Has Anyone Gotten HIV When They Were on PrEP?

    Pre-exposure prophylaxis (PrEP) was initially approved by the US Food and Drug Administration (FDA) in July 2012 due to its exceptional ability to prevent new HIV acquisitions. One of the persisting fears people may have when starting PrEP is wondering whether a risk remains of contracting HIV while on PrEP without using an additional barrier method (i.e., condoms) that we've become accustomed to seeing as the gold standard definition of "safe sex."

    October 13, 2020
    PrEP
    The Body

  • New Once-a-Week Drug Could Be Part of Weekly Oral Treatment

    The HIV Glasgow 2020 virtual conference heard about two human studies of a new drug being developed by Merck & Co in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. This drug, MK-8507, could be given just once a week, according to these studies. Merck already has a drug, islatravir or MK-8591, which can be dosed once a week and is even under investigation as a potent form of post-exposure prophylaxis (PEP), for monthly oral dosing as pre-exposure prophylaxis (PrEP), or for even longer if given in the form of an implant.

    October 13, 2020
    PrEP, Treatment
    aidsmap

  • Invest More in HIV Prevention, Experts Tell FG

    Experts have called on the federal government and other stakeholders to invest more in efforts to prevent HIV infection human immunodeficiency virus, HIV prevention interventions while advocating for supportive policy and programmes.

    October 13, 2020
    PrEP
    Vanguard

  • Refined Mapping of HIV’s Reservoir Could Aid in Cure Research

    Researchers have developed a new method of assessing the HIV reservoir, the murkily amorphous entity that lives on in the body despite antiretroviral (ARV) treatment and that frustrates attempts to cure the virus. The central component of the viral reservoir is long-lived memory T cells that retain a recollection of specific pathogens. When such cells are infected by HIV and enter a resting state, they remain under the radar of ARVs, which work only when cells are replicating and churning out new copies of the virus.

    October 12, 2020
    Cure
    POZ

  • Combating Fraudulent Practices in Anti-Retroviral Drug Procurement

    It is estimated that 3.1 million Nigerians are living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS). To halt the spread and ensure that those living with the virus have easy access to anti-retroviral drugs, the Federal Government needs to discontinue engaging contractors in the procurement of anti-retroviral drugs.

    October 11, 2020
    Treatment
    The Guardian Nigeria

Published Research

Announcements